by Daniel Schwartz | Apr 4, 2026 | Clinical Trials
Access to Care SGLT2 Inhibitors at Low GFR: Are We Drawing the Line in the Wrong Place? The SGLT2 inhibitors have had a profound effect on chronic disease management, in particular, in those living with chronic kidney disease, heart failure, or seeking to reduce...
by Daniel Schwartz | Nov 28, 2022 | Clinical Trials, Health Policy
CLINICAL TRIALS Should patients with diabetes, CKD and proteinuria despite RAASi & SGLT2i be considered for add-on therapy with finerenone (triple therapy)? A recent Twitter thread: As a Canadian nephrologist, relevant & active national debate in light of...
by Daniel Schwartz | Nov 27, 2022 | Clinical Trials
CLINICAL TRIALS Most impactful clinical trials: slowing progression of chronic kidney disease This is a highly subjective list, but these trials have been included as they have had a meaningful impact on guidelines, patients and clinicians at a global scale. 1. IDNT:...
by Daniel Schwartz | Nov 24, 2022 | Clinical Trials
CLINICAL TRIALS 7 ways the EMPA-KIDNEY trial will impact clinical care in CKD EMPA-KIDNEY was a clinical trial testing whether taking a single pill of empagliflozin every day prevents worsening of kidney disease or deaths from heart disease in people who have chronic...
by Daniel Schwartz | Jun 17, 2017 | Clinical Trials
CLINICAL TRIALS Personalized decision support and the move from NNT to iNNT The SPRINT trial made waves in the field of hypertension, showing evidence for reduced hard clinical endpoints (a combined outcome of myocardial infarction, acute coronary syndrome not...
by Daniel Schwartz | Nov 15, 2015 | Clinical Trials
CLINICAL TRIALS Will SPRINT Change Our Systolic BP Target in Hypertensive Patients from 140 to 120 mm Hg? At last week’s Medicine rounds at the Royal Columbia Hospital, I presented the results from the recently published SPRINT trial. SPRINT Research Group, Wright JT...
Recent Comments